“This year's congress focuses on patient safety, IT and new technology, which makes it a perfect opportunity to showcase TetraGraph for an initiated audience. Both we and our new distributor in the Nordics Vingmed exhibits TetraGraph during the event”
The type of organ-specific measurement that OnZurf Probe enables is unique in its kind, and our hope with the study is to be able to increase understanding of the liver's metabolism by being able to follow the post-operative changes directly on the organ
The milestone payment is a result of our close collaboration and the intent is that Fukuda Denshi will commence the commercialization later in 2019 after regulatory approval. The collaboration is in line with our vision to become a global leader in the field of peri- and post-operative patient monitoring
CEO Lena Södström
We are continuing our expansion in Europe and together with our distributors we are building the foundation for growth in the field of Neuromuscular monitoring
I am thrilled that we have received the opportunity to display our cutting-edge technology at the Innovation Pavilion for the second year in a row. We will be able demonstrate TetraGraph and it’s single-use electrodes TetraSens to a large portion of key opinion leaders from the US
Being awarded for this year's Biotech Builder is honorable and an award that of course affects all of us who for several years worked strategically to take Senzime from a development company to a commercial company with presence on approximately 15 markets. We continually strenghten our market position by signing additional distributor agreements on new markets
When I summarize the second quarter of 2018, it is gratifying to note that the sale revenue from our TetraGraph system is gaining momentum. We are still in the initial commercialization phase but given the great interest in our products we estimate that we will increase sales significantly in the future. Also gratifying is that we continue associating partners and distributors within new markets. This means that, counting previous distribution and license agreements, we have now started commercialization in 15 markets outside Sweden.
“The beginning of 2018 has been characterized by a continued high pace, both in terms of sales and distribution agreements in new markets. The production set of the TetraGraph system is complete and sales have started. The level of interest in our products is high and we have already delivered some thirty systems. During the quarter, we have signed distribution agreements with new partners in Spain, Portugal, South Korea, and after the reporting period, also in Belgium, the Netherlands, Luxembourg, Austria, the Czech Republic and Slovakia. Together with earlier distribution agreements and the licensing agreement with Fukuda Denshi in Japan, we now have distribution agreements in 13 markets outside Sweden. We expect that distribution agreements for additional markets will be signed during the current year.”
We are continuing to establish distribution networks throughout Europe. With Innomed, Intramed and A.M.I., we have signed agreements with experienced organizations that through their vast networks will be great partners when marketing TetraGraph on their respective market.
We have had a great deal of interest from South Korean clinicians and are happy that we can initiate the regulatory process together with Unimedics for commencing sales in South Korea during next year. Unimedics has the infrastructure and experience needed to make the TetraGraph into a market leader in South Korea
EIKOS Care Medical and Geranswers Medical Solutions are ideal partners with complementary product portfolios and extensive connections in the anesthesia field within their home markets. The distributors have the infrastructure and experience needed to make TetraGraph market leader in these countries
This is a milestone for Senzime as it allows critical patient information provided by the TetraGraph to be displayed on all Philips IntelliVue patient monitors worldwide. Our data will be treated no differently than any other data in the system, thus enabling the user to integrate it in their standard Patient Data Management System.
Continuous sampling in patients undergoing surgery may provide an opportunity to detect early complications. The clinical market seeks products that allow continuous sampling and monitoring of tissue substances to detect complications after surgery and control interventions. The CE mark of OnZurf Probe is an important milestone for Senzime and we will immediately initiate launch in Europe
The CE mark is a major milestone for Senzime, we will immediately commence the market roll-out of the TetraGraph system initially in Europe followed by the US and rest of the world. The TetraGraph will allow physicians to monitor the effects of neuromuscular blocking drugs perioperatively and ensure that patients can breathe spontaneously which will prevent complications and hence lower healthcare costs
This consensus statement clearly outlines the patient safety problems due to residual neuromuscular block. Our EMG-based monitor, the TetraGraph, will be launched shortly, contributing to enhanced patient safety.
These results comparing the TetraGraph to the former golden standard TOF-Watch validate our product and will provide anesthesiologists an accurate, easy to use monitor that can help prevent complications, avoid unnecessary patient suffering and save medical costs
CEO Lena Söderström
We are in the final stage regarding CE marking for TetraGraph and OnZurf probe. This means that we are expecting an extremely exciting time with a broad market launch of our products, where we are already experiencing a high demand
Leuag is a great partner for several reasons. They have a complementary product portfolio, the network and the experience needed to make the TetraGraph a market leader in Switzerland. CE marking is in its final phase and sales will commence directly after this.